BMRN — BioMarin Pharmaceutical · catalysts, narrative & risks

Snapshot (as of Oct 2, 2026)

BioMarin closed at $57.18 on October 2, 2026, down 2.16% on the day, with after-hours trading at ~$57.34 [8], [9]. The stock is roughly 18% below its 52-week high of ~$70.24 (set in August 2026) and sits near its 52-week low, with a market capitalization of about $11.1B [9]. This follows a meaningful decline: the stock traded near $69 in late August, ~$67 in early September, and ~$57 by early October, with year-to-date returns turning negative from around +11% in early September to about -3.8% by early October [1], [9].

Recent Catalysts (last ~1–3 months)